Please try another search
For the three months ended 31 March 2021,Constellation Pharmaceuticals Inc revenues was notreported. Net loss increased 57% to $40.1M. Higher net lossreflects Research and development - Balancing increase of50% to $28.5M (expense), Stock-based Compensation in SGAincrease from $1.6M to $3.2M (expense), Stock-basedCompensation in R&D increase from $1M to $2.3M (expense).
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -40.23 | -37.4 | -33.38 | -29.59 |
Net Income | -40.07 | -37.38 | -33.78 | -29.75 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 402.66 | 441.85 | 505.45 | 534.8 |
Total Liabilities | 25.34 | 31.13 | 62.68 | 62.82 |
Total Equity | 377.32 | 410.72 | 442.77 | 471.98 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -39.74 | -111.42 | -77.87 | -47.06 |
Cash From Investing Activities | -11.21 | -208.9 | -323.07 | -291.3 |
Cash From Financing Activities | 1.24 | 152.49 | 183.61 | 183.14 |
Net Change in Cash | -49.71 | -167.83 | -217.34 | -155.22 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review